id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-282252-07uzz649	Sahu, Kamal Kant	Convalescent Plasma Therapy: A Passive Therapy for An Aggressive COVID‐19	2020-05-21		.txt	text/plain	1366	94	55	The basic concept for use of convalescent plasma in COVID-19 is as a delivery system for viral neutralizing antibodies, that is to confer passive immunity. Considering the aforementioned limitations and the potential risks, appropriate triage systems should be utilized; hence, plasma therapy use is currently restricted only to critically ill patients. The FDA recommends two clinical indications for the current usage of convalescent plasma therapy in COVID-19 patients(12) Scenario A (Severe disease) which is defined as one or more of the following: On April 3, 2020, the FDA cleared the path for the use of this potential lifesaving therapy under any of the following three routes[1] enrollment in a clinical trial, [2] via the national expanded access treatment protocol, and [3] under a single patient emergency investigational new drug application (eIND). Lacking a vaccine and with limited antiviral options against SARS-CoV-2, this is an ideal time to try convalescent plasma therapy in COVID-19 patients. Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients	./cache/cord-282252-07uzz649.txt	./txt/cord-282252-07uzz649.txt